The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
The drug resistance limits the optimal efficacy of drugs during target therapies for lung cancer and requires the development of precision medicine to identify and develop new highly selective drugs and more precise tailoring of medicine to the target population. Lung cancer heterogeneity as a potential cause of drug resistance to targeted therapy may foster tumor evolution and adaptation and fade...
Recent researches revealed that phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) plays an important role in the development of drug resistance, reducing the anti-tumour activity of cytotoxic drugs, such as docetaxel (DTX). The aim of this reported work has been to evaluate DTX and the PI3K/Akt inhibitor perifosine co-loaded Fol/R7 (folate/R7) nanoparticles (NPs) for enhancing anti-cancer activity...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.